期刊
RSC ADVANCES
卷 12, 期 32, 页码 20432-20446出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2ra01999j
关键词
-
资金
- High Force Research
Nucleic Acid Therapeutics (NATs) have gained importance in the management and treatment of genetic diseases. Givosiran, which takes advantage of the interaction between ASGPR and GalNAc, highlights the value of targeted moieties. Through exploring the history of GalNAc as a ligand and identifying other potential oligosaccharides for NAT delivery, this review provides opportunities for further research.
Nucleic Acid Therapeutics (NATs) are establishing a leading role for the management and treatment of genetic diseases following FDA approval of nusinersen, patisiran, and givosiran in the last 5 years, the breakthrough of milasen, with more approvals undoubtedly on the way. Givosiran takes advantage of the known interaction between the hepatocyte specific asialoglycoprotein receptor (ASGPR) and N-acetyl galactosamine (GalNAc) ligands to deliver a therapeutic effect, underscoring the value of targeting moieties. In this review, we explore the history of GalNAc as a ligand, and the paradigm it has set for the delivery of NATs through precise targeting to the liver, overcoming common hindrances faced with this type of therapy. We describe various complex oligosaccharides (OSs) and ask what others could be used to target receptors for NAT delivery and the opportunities awaiting exploration of this chemical space.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据